SG11201607086QA - Novel methods for inducing an immune response - Google Patents

Novel methods for inducing an immune response

Info

Publication number
SG11201607086QA
SG11201607086QA SG11201607086QA SG11201607086QA SG11201607086QA SG 11201607086Q A SG11201607086Q A SG 11201607086QA SG 11201607086Q A SG11201607086Q A SG 11201607086QA SG 11201607086Q A SG11201607086Q A SG 11201607086QA SG 11201607086Q A SG11201607086Q A SG 11201607086QA
Authority
SG
Singapore
Prior art keywords
inducing
immune response
novel methods
novel
methods
Prior art date
Application number
SG11201607086QA
Other languages
English (en)
Inventor
William Ripley Ballou Jr
Arnaud Michel Didierlaurent
Der Most Robbert Gerrit Van
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of SG11201607086QA publication Critical patent/SG11201607086QA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
SG11201607086QA 2014-04-02 2015-04-02 Novel methods for inducing an immune response SG11201607086QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1405921.6A GB201405921D0 (en) 2014-04-02 2014-04-02 Novel methods for inducing an immune response
PCT/EP2015/057424 WO2015150568A1 (en) 2014-04-02 2015-04-02 Novel methods for inducing an immune response

Publications (1)

Publication Number Publication Date
SG11201607086QA true SG11201607086QA (en) 2016-09-29

Family

ID=50737873

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201607086QA SG11201607086QA (en) 2014-04-02 2015-04-02 Novel methods for inducing an immune response

Country Status (18)

Country Link
US (3) US10688168B2 (zh)
EP (2) EP3125930B1 (zh)
JP (2) JP6645982B2 (zh)
KR (2) KR20230075525A (zh)
CN (2) CN106456738B (zh)
AR (1) AR099960A1 (zh)
AU (1) AU2015239025B2 (zh)
BE (1) BE1022355B1 (zh)
BR (2) BR112016022787A2 (zh)
CA (2) CA2943711A1 (zh)
EA (1) EA037405B1 (zh)
ES (2) ES2853773T3 (zh)
GB (1) GB201405921D0 (zh)
IL (1) IL247493B (zh)
MX (3) MX2016012982A (zh)
SG (1) SG11201607086QA (zh)
WO (2) WO2015150567A1 (zh)
ZA (1) ZA201605955B (zh)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201405921D0 (en) * 2014-04-02 2014-05-14 Glaxosmithkline Biolog Sa Novel methods for inducing an immune response
GB201621686D0 (en) * 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response
EP3630176A1 (en) 2017-05-30 2020-04-08 GlaxoSmithKline Biologicals S.A. Methods for manufacturing an adjuvant
US11591364B2 (en) 2017-12-01 2023-02-28 Glaxosmithkline Biologicals Sa Saponin purification
CA3142300A1 (en) 2019-06-05 2020-12-10 Glaxosmithkline Biologicals Sa Saponin purification
CN113125756B (zh) * 2020-07-15 2022-10-25 南京岚煜生物科技有限公司 抗体标准品赋值和抗原中和当量确定的方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US152200A (en) * 1874-06-16 Improvement in garters
US1002607A (en) * 1905-08-28 1911-09-05 John Willard Taylor Paper pulley.
UA56132C2 (uk) * 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
PL376792A1 (pl) 2002-10-23 2006-01-09 Glaxosmithkline Biologicals S.A. Sposoby szczepienia przeciwko malarii
ES2371175T3 (es) 2004-10-14 2011-12-28 Crucell Holland B.V. Vacunas de sensibilización/refuerzo de malaria.
SI2457926T1 (sl) * 2005-04-29 2015-01-30 Glaxosmithkline Biologicals S.A. Nov postopek za preprečevanje ali zdravljenje infekcije z M. tuberculosis
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
CA2668100C (en) * 2006-11-01 2014-12-23 Immport Therapeutics, Inc. Compositions and methods for immunodominant antigens
CN101675068A (zh) * 2007-03-02 2010-03-17 葛兰素史密丝克莱恩生物有限公司 新的方法和组合物
TW200908994A (en) * 2007-04-20 2009-03-01 Glaxosmithkline Biolog Sa Vaccine
EA022203B1 (ru) * 2008-07-25 2015-11-30 Глаксосмитклайн Байолоджикалс С.А. Способы и композиции для лечения или предупреждения туберкулёза
PL2315834T3 (pl) * 2008-07-25 2018-12-31 Glaxosmithkline Biologicals S.A. Białko rv2386c związane z gruźlicą, jego kompozycje i zastosowania
CN102164952B (zh) * 2008-07-25 2016-05-25 葛兰素史密丝克莱恩生物有限公司 新型组合物和方法
SG182573A1 (en) * 2010-01-27 2012-08-30 Glaxosmithkline Biolog Sa Modified tuberculosis antigens
ME02380B (me) * 2010-12-14 2016-06-20 Glaxosmithkline Biologicals Sa Mikobakterijska antigena kompozicija
WO2015126930A2 (en) * 2014-02-18 2015-08-27 Stc.Unm Booster drug therapy for mycobacterium infections
GB201405921D0 (en) * 2014-04-02 2014-05-14 Glaxosmithkline Biolog Sa Novel methods for inducing an immune response
WO2015161853A1 (en) * 2014-04-24 2015-10-29 Statens Serum Institut New m.tuberculosis vaccines
GB201513176D0 (en) * 2015-07-27 2015-09-09 Glaxosmithkline Biolog Sa Novel methods for inducing an immune response

Also Published As

Publication number Publication date
MX2016012932A (es) 2016-12-07
EP3125930A1 (en) 2017-02-08
MX2016012982A (es) 2016-12-07
EP3125929B8 (en) 2023-12-27
EP3125929B1 (en) 2023-11-01
JP6645982B2 (ja) 2020-02-14
EA037405B1 (ru) 2021-03-25
US20170112914A1 (en) 2017-04-27
ES2853773T3 (es) 2021-09-17
US11951161B2 (en) 2024-04-09
BE1022355A1 (fr) 2016-02-16
GB201405921D0 (en) 2014-05-14
BR112016022787A2 (pt) 2018-03-27
US20200306353A1 (en) 2020-10-01
JP6655549B2 (ja) 2020-02-26
WO2015150568A1 (en) 2015-10-08
EP3125930B1 (en) 2020-12-02
BR112016022463A2 (pt) 2017-10-10
KR20160132115A (ko) 2016-11-16
CN106456738B (zh) 2021-06-29
AU2015239025A1 (en) 2016-09-22
MX2022013912A (es) 2022-12-13
WO2015150567A1 (en) 2015-10-08
KR20230075525A (ko) 2023-05-31
CA2943007A1 (en) 2015-10-08
BE1022355B1 (fr) 2016-03-26
IL247493A0 (en) 2016-11-30
EA201691638A1 (ru) 2017-04-28
CN106456738A (zh) 2017-02-22
US10688168B2 (en) 2020-06-23
IL247493B (en) 2022-08-01
ES2961840T3 (es) 2024-03-14
CN106456739A (zh) 2017-02-22
EP3125929C0 (en) 2023-11-01
EP3125929A1 (en) 2017-02-08
CA2943007C (en) 2024-01-09
AU2015239025B2 (en) 2018-01-25
AR099960A1 (es) 2016-08-31
CA2943711A1 (en) 2015-10-08
JP2017511324A (ja) 2017-04-20
ZA201605955B (en) 2019-04-24
US10624961B2 (en) 2020-04-21
JP2017511327A (ja) 2017-04-20
US20170136110A1 (en) 2017-05-18

Similar Documents

Publication Publication Date Title
IL257071A (en) New methods for inducing an immune response
EP3405190A4 (en) METHOD FOR TRIGGERING AN IMMUNE REACTION
GB201410971D0 (en) Vaccine
GB201410262D0 (en) Novel method
GB201413086D0 (en) Methods
GB201621686D0 (en) Novel methods for inducing an immune response
GB2526680B (en) Runway arrangement
ZA201605955B (en) Novel methods for inducing an immune response
GB201420047D0 (en) Force-measuring apparatus
IL252086A0 (en) New methods
GB201703042D0 (en) Mechanical apparatus
PL3169830T3 (pl) Urządzenie do elektrochlorowania
GB201409933D0 (en) Novel device
GB201408745D0 (en) Methods
LT3188755T (lt) Vakcina
GB201416773D0 (en) Novel Methods For Including An Imune Response
GB201402233D0 (en) Apparatus
GB201415685D0 (en) Methods
GB201417214D0 (en) Vaccine
GB2524070B (en) Suspension device
GB201417040D0 (en) Novel device
GB201414122D0 (en) Methods
GB201401565D0 (en) Novel method
GB201405509D0 (en) Novel Device
GB201413120D0 (en) Catapult